Amgen-AstraZeneca lung cancer drug combo boosts survival in late-stage trial
Sept 8 (Reuters) – Amgen’s targeted immunotherapy, Imdelltra, combined with AstraZeneca’s cancer drug Imfinzi, significantly improved overall survival in patients with extensive-stage small-cell lung cancer in a late-stage trial, the companies said on Tuesday. Here are some details: • The trial test























